Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
KN-93 (phosphate) is a potent and selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII) (Ki = 370 nM), inhibiting both the α- and β-subunits of CaMKII.1 It does not have significant effects on cAMP-dependent protein kinase, Ca2+/phospholipid-dependent protein kinase, myosin light chain kinase, or Ca2+ phosphodiesterase activity. It inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM).2 KN-93 can block voltage-gated potassium (Kv) channels when applied extracellularly, independent of its CaMKII action.3 More recently, KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cells.4,5,6
WARNING This product is not for human or veterinary use.
1. The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-
2. Inhibition of acid secretion in gastric parietal cells by the Ca2+/calmodulin-
3. KN-
4. Epac and phospholipase Cε regulate Ca2+ release in the heart by activation of protein kinase Cε and calcium-
5. Phosphorylation of serine 271 on 5-
6. Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-